Feedback / Questions
Tcelna (imilecleucel-T) - Acer Therap, EMD Serono
Lazard Capital Market Healthcare Conference
(Opexa Therapeutics)
-
Dec 18, 2012 -
"80% of subjects had no disease progression by EDSS at 2 years"
P2b data
•
Multiple Sclerosis
http://www.larvolonline.com/tlg/ccdb/OpexaTherapeuticsLazardCapitalMarketHealthcareConferenceNov142012.pdf
Dec 18, 2012
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.